Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease

Trial Profile

Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Sorafenib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms RESPECT
  • Sponsors Bayer
  • Most Recent Events

    • 01 Jun 2012 Planned end date changed from 1 Mar 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 19 Mar 2012 Planned End Date changed from 1 Nov 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 31 Oct 2011 Primary endpoint 'Progression-free-survival-duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top